Journal article
Effect of aspirin on all-cause mortality in the healthy elderly
JJ McNeil, MR Nelson, RL Woods, JE Lockery, R Wolfe, CM Reid, B Kirpach, RC Shah, DG Ives, E Storey, J Ryan, AM Tonkin, AB Newman, JD Williamson, KL Margolis, ME Ernst, WP Abhayaratna, N Stocks, SM Fitzgerald, SG Orchard Show all
New England Journal of Medicine | MASSACHUSETTS MEDICAL SOC | Published : 2018
Abstract
Background: In the primary analysis of the Aspirin in Reducing Events in the Elderly (ASPREE) trial, now published in the Journal, we report that the daily use of aspirin did not provide a benefit with regard to the primary end point of disability-free survival among older adults. A numerically higher rate of the secondary end point of death from any cause was observed with aspirin than with placebo. Methods: From 2010 through 2014, we enrolled community-dwelling persons in Australia and the United States who were 70 years of age or older (or ≥65 years of age among blacks and Hispanics in the United States) and did not have cardiovascular disease, dementia, or disability. Participants were r..
View full abstractGrants
Awarded by National Institutes of Health
Funding Acknowledgements
Funded by the National Institute on Aging and others; ASPREE ClinicalTrials.gov number, NCT01038583.